Clinical trials have used anti-CCL2 or anti-CCR2 antibody to inhibit CCL2 chemotactic TAMs in the local tumor microenvironment via CCR2 in addition to targeting MDSC drugs (such as all-trans retinoic acid), some chemotherapies (such as 5-fluorouracil and gemcitabine), and CXCR2 chemokine or its ligands (such as CXCL1 and CXCL2 blocking). This evidence concerns the gene CCR2 and neoplasm.